HOUSTON and QUITO, Ecuador

休斯顿和厄瓜多尔基多

,

，

Sept. 8, 2026

2026年9月8日

/PRNewswire/ -- IntelliGenome, Inc. today announced the appointment of SIMED S.A. as its exclusive distributor for the CRISPR-TB™ Blood Test in Peru and Ecuador.

/美通社/ -- IntelliGenome, Inc. 今日宣布任命 SIMED S.A. 为其在秘鲁和厄瓜多尔地区 CRISPR-TB™ 血液检测产品的独家经销商。

IntelliGenome received DIGEMID registration approval for the CRISPR-TB Blood Test in Peru, enabling commercial distribution in one of the region's most important tuberculosis markets. Under the new partnership, SIMED will initiate the product registration process in Ecuador.

IntelliGenome 获得秘鲁 DIGEMID 对 CRISPR-TB 血液检测的注册批准，从而得以在该地区最重要的结核病市场之一进行商业化分销。根据新的合作伙伴关系，SIMED 将启动在厄瓜多尔的产品注册流程。

CRISPR-TB is an innovative molecular blood test that detects circulating

CRISPR-TB 是一种创新的分子血液检测，可检测循环中的

Mycobacterium tuberculosis

结核分枝杆菌

cell-free DNA, representing a novel non-sputum approach to tuberculosis detection.

无细胞DNA，代表一种新型的无需痰液的结核病检测方法。

SIMED was selected for its strong expertise in tuberculosis diagnostics, molecular laboratory solutions, and established relationships with hospitals, reference laboratories, and public health institutions throughout Peru and Ecuador.

SIMED 因其在结核病诊断和分子实验室解决方案方面的强大专业能力，以及与秘鲁和厄瓜多尔各地的医院、参考实验室和公共卫生机构建立的稳固合作关系而获选。

'SIMED combines deep tuberculosis expertise with one of the region's strongest molecular diagnostics organizations, making them an ideal partner to accelerate adoption of CRISPR-TB across Peru and Ecuador,' said Kurt Wehrle, Vice President, Partnerships & Strategic Alliances at IntelliGenome.

IntelliGenome公司合作伙伴关系与战略联盟副总裁库尔特·韦尔勒表示：“SIMED将深厚的结核病专业知识与该地区最强大的分子诊断机构之一相结合，使其成为加速CRISPR-TB在秘鲁和厄瓜多尔应用的理想合作伙伴。”

The partnership significantly expands IntelliGenome's commercial presence in Latin America while strengthening SIMED's tuberculosis diagnostics portfolio with an innovative blood-based molecular technology.

此次合作显著扩大了IntelliGenome在拉丁美洲的商业布局，同时通过创新的血液分子检测技术增强了SIMED的结核病诊断产品组合。

'CRISPR-TB is an important addition to our tuberculosis diagnostics portfolio and reinforces our commitment to bringing innovative molecular technologies to laboratories throughout Peru and Ecuador.' said Abelardo Cruces, General Laboratory and Biosciences Business Manager at SIMED.

“CRISPR-TB 是我们结核病诊断产品组合的重要补充，也进一步彰显了我们致力于将创新分子技术带给秘鲁和厄瓜多尔各地实验室的承诺。”SIMED 公司通用实验室与生物科学业务经理阿贝尔达·克鲁塞斯表示。

About IntelliGenome

关于 IntelliGenome

IntelliGenome, Inc. is a molecular diagnostics company focused on the development and commercialization of innovative CRISPR-based diagnostic technologies. The company's CRISPR-TB™ platform utilizes proprietary molecular detection technologies to identify tuberculosis from blood samples and is being evaluated globally through collaborations with clinical, academic, and public health partners.

IntelliGenome, Inc. 是一家分子诊断公司，专注于开发和商业化创新的基于CRISPR的诊断技术。该公司的CRISPR-TB™平台利用专有的分子检测技术从血液样本中识别结核病，并通过与临床、学术和公共卫生合作伙伴的合作在全球范围内进行评估。

IntelliGenome is advancing both laboratory-based and near-patient testing solutions to expand access to tuberculosis diagnostics worldwide..

IntelliGenome 正在推进基于实验室和近患者检测的解决方案，以扩大全球结核病诊断的可及性。

About SIMED

关于SIMED

Founded in 1985, SIMED S.A. is one of the leading providers of diagnostic, laboratory, and life science solutions in Peru and Ecuador. Through long-standing partnerships with many of the world's leading healthcare companies, SIMED supports hospitals, public health institutions, clinical laboratories, and research organizations with advanced technologies and specialized technical expertise..

SIMED S.A. 成立于1985年，是秘鲁和厄瓜多尔领先的诊断、实验室及生命科学解决方案提供商之一。通过与众多全球领先医疗健康企业建立的长期合作伙伴关系，SIMED 为医院、公共卫生机构、临床实验室和研究组织提供先进技术和专业技术支持。

Media Contact:

媒体联系人：

Kurt Wehrle

库尔特·韦尔勒

Vice President, Partnerships & Strategic Alliances

副总裁，合作伙伴关系与战略联盟

IntelliGenome, Inc.

IntelliGenome公司

[email protected]

[email protected]

Mobile: (847)542-1542

手机：(847)542-1542

SOURCE IntelliGenome

来源 IntelliGenome

21

二十一

%

%

more press release views with

更多新闻稿浏览量

Request a Demo

申请演示